Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of lenalidomide in treating
young patients with relapsed or refractory solid tumors or myelodysplastic syndromes.
Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking
blood flow to the cancer. It may also stimulate the immune system in different ways and stop
cancer cells from growing.